Company / Cost of Revenue
LENZ Therapeutics, Inc. Cost of Revenue History
FY2025-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$418.0K
FY2025
5-year range
$418.0K / $418.0K
FY2025-FY2025
Trend
-
vs FY2024
Sector context
#81 of 85
Health Care
What the data says
Among 85 Health Care companies, LENZ Therapeutics, Inc. is in the top 5% for cost of revenue.
Based on SEC 10-K filings.
$418,000 in FY2025.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 85This company $418.0K Sector average $2.0B
▼
-100.0% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $418.0K | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026